Advertisement

Drudge Retort: The Other Side of the News
Tuesday, June 17, 2025

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency. The federal outfit's "Commissioner's National Priority Voucher" (CNPV) program will include a "limited number of vouchers" for "companies aligned with U.S. national priorities," according to a June 17 press release.

More

Comments

Admin's note: Participants in this discussion must follow the site's moderation policy. Profanity will be filtered. Abusive conduct is not allowed.

More from the article...

..."These vouchers are non-transferrable," an FDA spokesperson told Fierce Biotech. "However, they will remain valid through changes in company ownership."

FDA Commissioner Marty Makary, M.D., will determine a company's eligibility for CNPV by assessing whether the biopharma is addressing several national priorities. ...


#1 | Posted by LampLighter at 2025-06-17 10:26 PM | Reply

So, Pres Trump seems to be inserting himself into the FDA drug approval process?

What might that mean?

#2 | Posted by LampLighter at 2025-06-17 10:27 PM | Reply

You pay if you wanna play, capiche?

#3 | Posted by LegallyYourDead at 2025-06-18 12:02 AM | Reply

The following HTML tags are allowed in comments: a href, b, i, p, br, ul, ol, li and blockquote. Others will be stripped out. Participants in this discussion must follow the site's moderation policy. Profanity will be filtered. Abusive conduct is not allowed.

Anyone can join this site and make comments. To post this comment, you must sign it with your Drudge Retort username. If you can't remember your username or password, use the lost password form to request it.
Username:
Password:

Home | Breaking News | Comments | User Blogs | Stats | Back Page | RSS Feed | RSS Spec | DMCA Compliance | Privacy

Drudge Retort